Network pharmacology of Astragalus membranaceusAtractylodes macrocephala in the treatment of osteoporotic fractures
MAO Yinfeng1, CUI Songxiang1, HUA Zhen2, PENG Hongcheng1, WANG Jianwei2#br#
(1. Graduate School, Nanjing University of Chinese Medicine, Nanjing Jiangsu 210023；2. Department of Orthopedics and Traumatology, Wuxi Affiliated Hospital, Nanjing University of Chinese Medicine, Wuxi Jiangsu 214071, China)
Abstract：Objective:To explore the potential mechanism of Astragalus membranaceus and Atractylodes macrocephala in the treatment of osteoporotic fracture (OPF) based on network pharmacology. Methods: The active components and action targets of Astragalus membranaceus and Atractylodes macrocephala were screened by pharmacologic database and Analysis Platform (TCMSP) . GeneCards, OMIM and TTD databases related to disease targets were retrieved to screen the action targets of OPF, and then the intersection core targets of Astragalus membranaceus, Atractylodes macrocephala membranaceus and OPF were screened. Cytoscape 3.7.1 software was used to construct a compoundtargetdisease network, and DAVID database was used to analyze the enrichment of GO function and KEGG pathway. Results: Based on TCMSP database, 19 active components and 115 intersection targets of Astragalus membranaceusAtractylodes for OPF were screened. A total of 568 items were obtained by GO functional enrichment analysis, including 433 biological process items, 43 cell composition items and 92 molecular function items. KEGG pathway enrichment analysis revealed 111 items, including AGE-RAGE, IL-17, TNF, prostate cancer, Toll-like receptor, HIF-1, NF-κB signaling pathway, etc. Conclusion: Astragalus membranaceus and Atelectylodes atelectylodes may regulate inflammatory response and internal balance of osteoclasts by regulating TNF, NF-κB and HIF-1 signaling pathways, and thus exert therapeutic actions on OPF.
［5］Liu JF, Hu AN, Zan JF, et al. Network pharmacology deciphering mechanisms of volatiles of wendan granule for the treatment of alzheimer′s disease［J］. Evid Based Complement Alternat Med, 2019, 2019: 1-12.
［8］Wong SK, Chin KY, ImaNirwana S. Quercetin as an agent for protecting the bone:a review of the current evidence［J］. Int J Mol Sci, 2020, 21(17): 6448.
［9］Kong X, Wang F, Niu Y, et al. A comparative study on the effect of promoting the osteogenic function of osteoblasts using isoflavones from radix astragalus［J］. Phytother Res, 2018, 32(1): 115-124.
［11］Wong SK, Chin KY, ImaNirwana S. The osteoprotective effects of kaempferol: the evidence from in vivo and in vitro studies ［J］. Drug Des Devel Ther, 2019, 13: 3497-3514.
［13］Lin TH, Pajarinen J, Lu L, et al.NFκB as a therapeutic target in inflammatoryassociated bone diseases［J］. Adv Protein Chem Struct Biol, 2017, 107: 117-154.
［14］Zhao B.TNF and bone remodeling.［J］. Curr Osteoporos Rep, 2017, 15(3): 126-134.
［16］Yang T, Martin P, Fogarty B, et al. Exosome delivered anticancer drugs across the bloodbrain barrier for brain cancer therapy in Daniorerio［J］. Pharm Res, 2015, 32(6): 2003-2014.
［17］AlonsoPérez A, FrancoTrepat E, GuillánFresco M, et al. Role of tolllike receptor 4 on osteoblast metabolism and function［J］. Front Physiol, 2018, 9: 504
［18］Le Goff B, Bouvard B, Lequerre T, et al. Implication of IL17 in bone loss and structural damage in inflammatory rheumatic diseases［J］. Mediators Inflamm, 2019, 2019: 1-9.
